# Clinical Trial Landscape: 06_breast_her2_positive

*Generated: 2026-01-05 18:30:22*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 14

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 35 | ███████ 35.0% |
| Phase 1 | 20 | ████ 20.0% |
| Phase 1/Phase 2 | 17 | ███ 17.0% |
| Phase 3 | 15 | ███ 15.0% |
| Not Applicable | 6 | █ 6.0% |
| Unknown | 3 |  3.0% |
| Phase 2/Phase 3 | 2 |  2.0% |
| Early Phase 1 | 1 |  1.0% |
| Phase 4 | 1 |  1.0% |

## Status Distribution

- **Recruiting**: 97 (97.0%)
- **Not yet recruiting**: 3 (3.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| Mayo Clinic | 5 |
| Dana-Farber Cancer Institute | 4 |
| National Cancer Institute (NCI) | 4 |
| Baylor College of Medicine | 2 |
| Stanford University | 2 |
| Laura Huppert, MD, BA | 2 |
| Weill Medical College of Cornell University | 2 |
| Hoffmann-La Roche | 2 |
| AstraZeneca | 2 |
| H. Lee Moffitt Cancer Center and Research Institut | 2 |
| Stemline Therapeutics, Inc. | 2 |
| Olema Pharmaceuticals, Inc. | 2 |
| Genmab | 2 |
| Novartis Pharmaceuticals | 2 |
| Analog Device, Inc. | 2 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Biospecimen Collection | 10 |
| Abemaciclib | 9 |
| Paclitaxel | 7 |
| Pembrolizumab | 6 |
| Placebo | 6 |
| Questionnaire Administration | 6 |
| Everolimus | 5 |
| Fulvestrant | 5 |
| Palbociclib | 4 |
| Letrozole | 4 |
| Ribociclib | 4 |
| Trastuzumab | 4 |
| Carboplatin | 4 |
| Computed Tomography | 4 |
| Tamoxifen | 3 |
| Trastuzumab Deruxtecan | 3 |
| BGB-11417 | 3 |
| Quality-of-Life Assessment | 3 |
| Alpelisib | 3 |
| Tucatinib | 3 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| South Korea | 21 |
| Spain | 21 |
| France | 17 |
| Italy | 17 |
| Australia | 16 |
| Germany | 16 |
| United Kingdom | 16 |
| Belgium | 13 |
| Poland | 13 |
| Canada | 12 |
| China | 10 |
| Taiwan | 9 |
| Turkey (Türkiye) | 9 |
| Brazil | 8 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| HER2 positive | manual | 1.0 |
| HER2positive | manual | 0.9 |
| HER2-positive | manual | 0.9 |
| ER positive | manual | 1.0 |
| ERpositive | manual | 0.9 |
| ER-positive | manual | 0.9 |
| PR negative | manual | 1.0 |
| PRnegative | manual | 0.9 |
| PR-negative | manual | 0.9 |
| breast cancer | manual | 1.0 |
| HER2 positive breast cancer | manual | 1.0 |
| ER positive breast cancer | manual | 1.0 |
| PR negative breast cancer | manual | 1.0 |
| BC | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT06224673](https://clinicaltrials.gov/study/NCT06224673) | Phase 2 | Not yet recruiting | Laura Huppert, MD, B... | Phase II Open-label Study of ARX788... |
| [NCT05874193](https://clinicaltrials.gov/study/NCT05874193) | Phase 2 | Not yet recruiting | Cristiana Costa Chas... | A Collaborative Community Effort Us... |
| [NCT06525766](https://clinicaltrials.gov/study/NCT06525766) | Phase 2 | Recruiting | Mayo Clinic | Single Arm Pilot Trial of Adaptive ... |
| [NCT06619236](https://clinicaltrials.gov/study/NCT06619236) | Phase 3 | Recruiting | Genmab | A Phase 3 Randomized, Open-label St... |
| [NCT06572618](https://clinicaltrials.gov/study/NCT06572618) | Phase 2 | Recruiting | City of Hope Medical... | A Phase 2 Study of BTK Inhibitor Ne... |
| [NCT06695845](https://clinicaltrials.gov/study/NCT06695845) | Phase 2 | Recruiting | Jazz Pharmaceuticals | A Phase 2, Open-label, Multicenter ... |
| [NCT06712316](https://clinicaltrials.gov/study/NCT06712316) | Phase 2/Phase 3 | Recruiting | BioNTech SE | A Phase II/III, Multisite, Randomiz... |
| [NCT06677190](https://clinicaltrials.gov/study/NCT06677190) | Phase 2 | Recruiting | Dana-Farber Cancer I... | A Phase II Trial of Belzutifan in P... |
| [NCT05989828](https://clinicaltrials.gov/study/NCT05989828) | Phase 1 | Recruiting | University of Southe... | Phase Ib Clinical Trial of Autologo... |
| [NCT06630234](https://clinicaltrials.gov/study/NCT06630234) | Phase 1/Phase 2 | Recruiting | Deciphera Pharmaceut... | A Master Protocol for the Multi-coh... |
| [NCT06428396](https://clinicaltrials.gov/study/NCT06428396) | Phase 2 | Recruiting | Merck Sharp & Dohme ... | A Phase 2, Randomized, Active-contr... |
| [NCT06678269](https://clinicaltrials.gov/study/NCT06678269) | Phase 1 | Recruiting | Memorial Sloan Kette... | A Phase I Study of Concurrent Abema... |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Phase 1 | Recruiting | Zymeworks BC Inc. | A Phase 1, Open-label, Multicenter ... |
| [NCT06562192](https://clinicaltrials.gov/study/NCT06562192) | Phase 1 | Recruiting | Novartis Pharmaceuti... | Phase I Open-label, Multi-center St... |
| [NCT06623201](https://clinicaltrials.gov/study/NCT06623201) | Phase 1 | Recruiting | Nathalie Zeitouni | Blue-Light Photodynamic Therapy and... |
| [NCT06184750](https://clinicaltrials.gov/study/NCT06184750) | Phase 2 | Recruiting | National Cancer Inst... | Refining Tamoxifen Dose for Premeno... |
| [NCT06473597](https://clinicaltrials.gov/study/NCT06473597) | Phase 4 | Recruiting | Antonios Likourezos | A Comparison of Rimegepant Orally D... |
| [NCT06538389](https://clinicaltrials.gov/study/NCT06538389) | Phase 2 | Recruiting | City of Hope Medical... | High Cannabidiol (CBD) Standardized... |
| [NCT06139107](https://clinicaltrials.gov/study/NCT06139107) | Phase 1 | Recruiting | Mridula George, MD | RADIANT Study: Pre-op Radiation Wit... |
| [NCT06439693](https://clinicaltrials.gov/study/NCT06439693) | Phase 2 | Recruiting | Dana-Farber Cancer I... | A Single-Arm, Phase II Study of Seq... |
| [NCT06401889](https://clinicaltrials.gov/study/NCT06401889) | N/A | Recruiting | Mayo Clinic | Enhancing Skin Appearance and Quali... |
| [NCT06590857](https://clinicaltrials.gov/study/NCT06590857) | Phase 1/Phase 2 | Recruiting | RayzeBio, Inc. | Phase 1b/2 Open-label Trial of 225A... |
| [NCT06154590](https://clinicaltrials.gov/study/NCT06154590) | N/A | Not yet recruiting | DR. DIANE CHISESI NF... | Anastrozole Adjuvant Trial - Study ... |
| [NCT06356311](https://clinicaltrials.gov/study/NCT06356311) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Multicenter, Open-label,... |
| [NCT05916196](https://clinicaltrials.gov/study/NCT05916196) | Phase 2 | Recruiting | Abramson Cancer Cent... | [18F]FLUOROESTRADIOL (FES) PET/CT I... |
| [NCT06149481](https://clinicaltrials.gov/study/NCT06149481) | Phase 1/Phase 2 | Recruiting | National Cancer Inst... | Phase I/II Study of the Combination... |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Phase 2 | Recruiting | Mirati Therapeutics ... | A Randomized Study of Two Dosing Re... |
| [NCT06227377](https://clinicaltrials.gov/study/NCT06227377) | Phase 1 | Recruiting | Quanta Therapeutics | A Phase 1 Trial Evaluating the Safe... |
| [NCT06176261](https://clinicaltrials.gov/study/NCT06176261) | Phase 2 | Recruiting | Sarah Sammons, MD | DATO-BASE: A Phase 2 Trial of DATOp... |
| [NCT05950945](https://clinicaltrials.gov/study/NCT05950945) | Phase 3 | Recruiting | Daiichi Sankyo | A Phase 3b, Multicenter, Global, In... |
| [NCT06234397](https://clinicaltrials.gov/study/NCT06234397) | Phase 1 | Recruiting | Hanmi Pharmaceutical... | A Phase I, Open-Label, Multinationa... |
| [NCT06119581](https://clinicaltrials.gov/study/NCT06119581) | Phase 3 | Recruiting | Eli Lilly and Compan... | SUNRAY-01, A Global Pivotal Study i... |
| [NCT04234048](https://clinicaltrials.gov/study/NCT04234048) | Phase 1 | Recruiting | SciTech Development,... | A Phase 1a/1b Trial in Relapsed/Ref... |
| [NCT06007131](https://clinicaltrials.gov/study/NCT06007131) | Not Applicable | Recruiting | Analog Device, Inc. | Feasibility and Efficacy Study of t... |
| [NCT06035744](https://clinicaltrials.gov/study/NCT06035744) | Phase 1 | Recruiting | Cullinan Therapeutic... | A Phase 1 First-in-Human Study to I... |
| [NCT06058377](https://clinicaltrials.gov/study/NCT06058377) | Phase 3 | Recruiting | National Cancer Inst... | Phase III Trial Of Neoadjuvant Durv... |
| [NCT06016738](https://clinicaltrials.gov/study/NCT06016738) | Phase 3 | Recruiting | Olema Pharmaceutical... | A Phase 3 Randomized, Open-Label St... |
| [NCT05696626](https://clinicaltrials.gov/study/NCT05696626) | Phase 3 | Recruiting | Sermonix Pharmaceuti... | An Open Label, Randomized, Multicen... |
| [NCT06055881](https://clinicaltrials.gov/study/NCT06055881) | Not Applicable | Recruiting | Mayo Clinic | Primary Breast Oligoprogressive Sit... |
| [NCT06028022](https://clinicaltrials.gov/study/NCT06028022) | Phase 2 | Recruiting | Mayo Clinic | Reishi Mushroom Extract for Fatigue... |
| [NCT06099769](https://clinicaltrials.gov/study/NCT06099769) | Phase 2 | Recruiting | Memorial Sloan Kette... | A RANDOMIZED, PHASE II STUDY OF ENZ... |
| [NCT05888493](https://clinicaltrials.gov/study/NCT05888493) | Phase 3 | Recruiting | Novartis Pharmaceuti... | A Randomized, Open-label, Multi-cen... |
| [NCT06062498](https://clinicaltrials.gov/study/NCT06062498) | Phase 2 | Recruiting | Northwestern Univers... | Randomized Phase II Study of Elaces... |
| [NCT05903092](https://clinicaltrials.gov/study/NCT05903092) | Phase 2 | Recruiting | Hirva Mamdani | A Phase II Trial of MOnaliZumab in ... |
| [NCT05894239](https://clinicaltrials.gov/study/NCT05894239) | Phase 3 | Recruiting | Hoffmann-La Roche | A Phase III, Multicenter, Randomize... |
| [NCT05879926](https://clinicaltrials.gov/study/NCT05879926) | Phase 3 | Recruiting | NRG Oncology | A Phase III Adjuvant Trial Evaluati... |
| [NCT05748834](https://clinicaltrials.gov/study/NCT05748834) | Phase 2 | Recruiting | SCRI Development Inn... | Phase 2 Single Arm Trial With a Saf... |
| [NCT05978518](https://clinicaltrials.gov/study/NCT05978518) | Phase 2/Phase 3 | Recruiting | Analog Device, Inc. | Feasibility and Efficacy Study of t... |
| [NCT05985655](https://clinicaltrials.gov/study/NCT05985655) | Phase 1/Phase 2 | Recruiting | Exscientia AI Ltd., ... | A Phase 1/2 Open-label Multicenter ... |
| [NCT05783609](https://clinicaltrials.gov/study/NCT05783609) | Phase 2 | Recruiting | Reid Merryman, MD | A Phase 2 Study of Epcoritamab and ... |

*... and 50 more trials (see trials.csv for full list)*
